Last reviewed · How we verify
Nutropin AQ
Nutropin AQ is a Recombinant human growth hormone Small molecule drug developed by Children's Mercy Hospital Kansas City. It is currently FDA-approved for Growth hormone deficiency in children, Growth hormone deficiency in adults, Short stature associated with Turner syndrome. Also known as: Growth Hormone, Growth Hormone (Nutropin AQ), Growth Hormone (GH), Growth hormone.
Nutropin AQ is a recombinant human growth hormone that binds to growth hormone receptors to stimulate growth and metabolic processes.
Nutropin AQ is a recombinant human growth hormone (rhGH) injection used to treat conditions such as Growth Hormone Deficiency, Prader-Willi Syndrome, Idiopathic Short Stature, Poor Ovarian Response, and Turner Syndrome. It stimulates growth, cell reproduction, and cell regeneration by increasing the production of insulin-like growth factor 1 (IGF-1) and affecting glucose and free fatty acid levels.
At a glance
| Generic name | Nutropin AQ |
|---|---|
| Also known as | Growth Hormone, Growth Hormone (Nutropin AQ), Growth Hormone (GH), Growth hormone |
| Sponsor | Children's Mercy Hospital Kansas City |
| Drug class | Recombinant human growth hormone |
| Target | Growth hormone receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Nutropin AQ (somatropin) is a synthetic form of human growth hormone produced via recombinant DNA technology. It activates growth hormone receptors on target tissues, promoting linear growth, protein synthesis, and lipolysis while reducing fat mass. It is used to treat growth hormone deficiency and other growth disorders in children and adults.
Approved indications
- Growth hormone deficiency in children
- Growth hormone deficiency in adults
- Short stature associated with Turner syndrome
- Idiopathic short stature
Common side effects
- Injection site reactions
- Headache
- Hypothyroidism
- Carpal tunnel syndrome
- Fluid retention
- Gynecomastia
Key clinical trials
- Human Models of Selective Insulin Resistance: Pancreatic Clamp (PHASE1)
- Pancreatic Clamp in NAFLD (PHASE1)
- Growth Hormone Therapy for Wasting in Cystic Fibrosis (PHASE1)
- Dexamethasone/Pancreatic Clamp P&F (PHASE1)
- Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children (PHASE3)
- Study of Testosterone and rHGH in FSHD (PHASE1)
- Growth Hormone Use in Adults With Prader-Willi Syndrome (PHASE3)
- Trial of Growth Hormone Therapy in Pediatric Crohn's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nutropin AQ CI brief — competitive landscape report
- Nutropin AQ updates RSS · CI watch RSS
- Children's Mercy Hospital Kansas City portfolio CI
Frequently asked questions about Nutropin AQ
What is Nutropin AQ?
How does Nutropin AQ work?
What is Nutropin AQ used for?
Who makes Nutropin AQ?
Is Nutropin AQ also known as anything else?
What drug class is Nutropin AQ in?
What development phase is Nutropin AQ in?
What are the side effects of Nutropin AQ?
What does Nutropin AQ target?
Related
- Drug class: All Recombinant human growth hormone drugs
- Target: All drugs targeting Growth hormone receptor
- Manufacturer: Children's Mercy Hospital Kansas City — full pipeline
- Therapeutic area: All drugs in Endocrinology
- Indication: Drugs for Growth hormone deficiency in children
- Indication: Drugs for Growth hormone deficiency in adults
- Indication: Drugs for Short stature associated with Turner syndrome
- Also known as: Growth Hormone, Growth Hormone (Nutropin AQ), Growth Hormone (GH), Growth hormone
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing